Journal
BULLETIN DU CANCER
Volume 110, Issue 2, Pages 201-211Publisher
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.bulcan.2022.09.010
Keywords
Cancer; Systemic treatment; End-of-life; Supportive care; Palliative care
Categories
Ask authors/readers for more resources
This study evaluated the use of palliative systemic treatments near end-of-life for patients with metastatic cancer at a French cancer institute. The results showed that 6.2% of the 452 patients received systemic treatment in the last 14 days of life, and 8.4% started a new systemic treatment in the last 30 days of life. Although our institute offers a good quality of end-of-life care, improvements should be made regarding prognostic estimation and integration of palliative care.
Examining the use of palliative systemic treatments near end-of-life for patients with metastatic cancer at a French cancer institute Background and objectives > Appropriate use of palliative systemic treatments near end-of-life is crucial to reduce aggressiveness of cancer care. The study's objective is to evaluate cancer quality -of-care near end-of-life in our cancer institute. Methods > From a retrospective cohort, we included all adults with metastatic solid cancers who died in 2019. The use of palliative systemic treatments close to death was measured from quality -of-care indicators described by Earle and al. The integration of supportive care into standard oncology care was also evaluated. All the information were collected from electronic records. Results > Of the 452 patients, 6.2% received systemic treatment in the last 14 days of life and 8.4% started a new systemic treatment in the last 30 days of life. Eighty six percent met a supportive care physician. This intervention was significantly less frequent in the TS<14 group than in the TS>30 group (71.4 % vs 89.5 % p = 0.021). The main reasons for first contact were pain (35 %), early palliative care (29 %) and then exclusive palliative care (17.5 %). Conclusion > Our institute offers a good quality of end-of-life care for patients with metastatic solid cancers. However, improvements should be done regarding prognostic estimation and integration of palliative care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available